SURI Simplify Propel Opportunities ETF
ETF on NYSE (US) · Actively managed · Listing
Changes appear once four weeks of holdings are on file.
Largest holding: Plains GP Holdings, L.P., 846,388 shares ($22.2M).
| Current positions Top 10 | % of book |
|---|---|
| Plains GP Holdings, L.P. PAGP $22.2M | 32.6% |
| SIMPLIFY E GOVT MONEY MKT ETF SBIL $10.8M | 15.8% |
| Achieve Life Sciences, Inc. ACHV $5.70M | 8.4% |
| Cash CASH $4.43M | 6.5% |
| Delcath Systems, Inc. DCTH $4.03M | 5.9% |
| ACHIEVE LIFE SCIENCES I WTS 30JUN30 $3.02M | 4.4% |
| Collegium Pharmaceutical, Inc. COLL $2.39M | 3.5% |
| Orchestra BioMed Holdings, Inc. OBIO $1.69M | 2.5% |
| Corcept Therapeutics Incorporated CORT $1.44M | 2.1% |
| Milestone Pharmaceuticals Inc. MIST $1.38M | 2.0% |
Slices are % of holdings value.
| Sectors | % of holdings value |
|---|---|
| Healthcare | 37.9% |
| Energy | 32.6% |
| Unclassified | 29.5% |
| Industries | % of holdings value |
|---|---|
| Oil & Gas Midstream | 32.6% |
| Biotechnology | 16.1% |
| Drug Manufacturers - Specialty & Generic | 11.9% |
| Medical Devices | 8.4% |
| Drug Manufacturers - General | 1.5% |
| Unclassified | 29.5% |
Source: the fund's own published holdings, the portfolio of Nov 17, 2026 (simplify.us). Cash and money-market lines are in the book and its value but are never counted as trades. Short positions are listed as such, at their (negative) printed value.
Objective
From the summary prospectus filed Oct 29, 2026.
The Simplify Propel Opportunities ETF (the "Fund" or "SURI") seeks long-term capital appreciation.
Principal investment strategies
The Fund is an actively managed exchange-traded fund ("ETF"). The Fund's investment adviser Simplify Asset Management Inc. (the "Adviser") collaborates with the Fund's sub-adviser, Propel Bio Management, LLC (the "Sub-Adviser"), to seek to achieve the Fund's investment objective. The Fund concentrates its investments (i.e., invests more than 25% of its net assets) in the securities of issuers in the biotechnology, pharmaceuticals, healthcare technology, and life science tools and services industries. Each of these industries are commonly categorized within the healthcare sector because they share similar economic features and regulatory constraints. The Fund also may invest in securities of issuers engaged in energy-related endeavors such as the production, generation, and sale of energy resources. The Sub-Adviser employs an actively managed opportunistic multi-asset strategy that focuses on common stock, preferred stock, convertible bonds, structured notes, corporate notes and bonds, and ETFs that primarily invest in the preceding security types. The Fund also may invest in money market funds. The Adviser employs a derivatives strategy to partially protect or enhance Fund returns. The Sub-Adviser is responsible for security selection and the Adviser is responsible for trade execution, regulatory oversight of the Fund and the derivatives strategy. The Fund invests without restriction as to security currency, issuer capitalization (including micro-capitalization), or country and without restriction as to debt credit quality, maturity, structure, or issuer type. Lower quality corporate debt is commonly known as a "junk bond." Junk bonds are generally rated lower than Baa3 by Moody's Investors Service, Inc. or lower than BBB- by Standard and Poor's Ratings Group or lower than BBB- by Fitch Ratings, Inc. The Fund may invest in privately placed and restricted securities (including 144A bonds). The Fund is classified as a "non-diversified" fund under the Investment Company Act of 1940, as amended, which means that the Fund may invest a higher percentage of its assets in a fewer number of issuers than is permissible for a "diversified" Fund. Sub-Adviser's Opportunistic Multi-Asset Strategy The Sub-Adviser selects securities that it believes present attractive investment opportunities, which may include securities that the Sub-Adviser believes are neglected and overlooked investments and present significant opportunities for capital appreciation. The Sub-Adviser uses fundamental, bottom-up analysis to identify securities that present attractive investment opportunities, which may include securities that the Sub-Adviser determines to be undervalued or present opportunities for growth. The Sub-Adviser selects debt or equity exposure based on its estimation of expected relative returns. The Sub-Adviser sells a security when it believes it is no longer undervalued or when more attractive investments are identified. Healthcare Sector Sub-Strategy The Sub-Adviser employs individuals who possess significant scientific, technical, operational, regulatory and commercial expertise to evaluate the science and prospects of healthcare sector companies as well as individuals with significant experience and expertise in identifying securities that present attractive investment opportunities, which may include securities that the Sub-Adviser determines to be undervalued or present opportunities for growth. Healthcare sector companies that the Fund typically includes in the portfolio are small to medium capitalization companies that may be in various stages of maturity. These may include "early-stage companies" which include those that routinely develop new products or services or are in the process of conducting clinical trials and may not yet be consistently profitable.
Management and Contact
- Adviser
- Simplify Asset Management Inc.
- Sub-adviser
- Propel Bio Management, LLC
- Portfolio managers
-
David Berns, PhD, Chief Investment Officer of the Adviser;
Jeff Schwarte, Chief Equity Strategist of the Adviser, Leen Kawas, Managing General Partner of the Sub-Adviser; and Xue Hua, Portfolio Manager of the Sub-Adviser; serve as portfolio managers for the Fund.
Dr. Berns, Ms. Kawas, and Ms. Hua have each served the Fund as a portfolio manager since December 2022.
Mr. Schwarte has served the Fund as a portfolio manager since November 2024.
Dr. Berns, Mr. Schwarte, Ms. Kawas, and Ms. Hua, are jointly and primarily responsible for the management of the Fund.
- Phone
- (855) 772-8488
- Website
- simplify.us/etfs
Track Record as of Dec 31, 2025
Average annual total returns from the summary prospectus. Returns in percent; periods over a year are annualized.
| 1 Year | Since Inception | |
|---|---|---|
| Return Before Taxes | 25.10% | 2.51% |
| Return After Taxes on Distributions | 16.88% | -3.98% |
| Return After Taxes on Distributions and Sale of Fund Shares | 14.29% | -0.93% |
| MSCI USA IMI Health Care Net Total Return USD Index (reflects no deduction for fees, expenses or taxes) | 14.91% | 6.88% |
| S&P 500 Index (reflects no deduction for fees, expenses or taxes) | 17.88% | 20.45% |
Holdings as of Nov 17, 2026
The full portfolio the fund publishes every business day on its website (simplify.us). Every line is listed: holdings we could identify link to their page, the rest (cash, options, swaps, private shares, securities we do not carry) are shown as the fund prints them. Short positions are negative. Change is the share count against Nov 16, 2026.
38 lines, 23 linked, weights sum to 100.01% · Actively managed (N-CEN)
| Holding | Ticker / identifier | Type | Shares | Change | Weight | Market value |
|---|---|---|---|---|---|---|
| PLAINS GP HLDGS L P | PAGP US72651A2078 | Equity | 846,388 | 0 | 32.57% | $ 22.184M |
| SIMPLIFY E GOVT MONEY MKT ETF | SBIL US82889N2696 | Fund | 107,300 | 0 | 15.79% | $ 10.758M |
| ACHIEVE LIFE SCIENCES INC USD 0.001 | QUIT US0044685008 | Equity | 932,105 | 0 | 8.37% | $ 5.704M |
|
Cash
|
CASH | Cash | 4,434,130.9441 | โ1,492.4886 | 6.51% | $ 4.434M |
| DELCATH SYS INC USD 0.01 | DCTH US24661P8077 | Equity | 207,999 | 0 | 5.92% | $ 4.029M |
|
ACHIEVE LIFE SCIENCES I WTS 30JUN30
|
US0044681874 | Warrant | 966,667 | 0 | 4.43% | $ 3.016M |
| COLLEGIUM PHARMACEUTICAL USD 0.001 | COLL US19459J1043 | Equity | 93,521 | 0 | 3.51% | $ 2.389M |
| ORCHESTRA BIOMED HLDGS I USD 0.0001 | OBIO US68572M1062 | Equity | 242,098 | 0 | 2.48% | $ 1.687M |
| CORCEPT THERAPEUTICS INC USD 0.001 | CORT US2183521028 | Equity | 20,568 | 0 | 2.12% | $ 1.441M |
| MILESTONE PHARMACEUTICALS INC NPV | MIST CA59935V1076 | Equity | 3,349,379 | 0 | 2.03% | $ 1.384M |
| PHATHOM PHARMACEUTICALS USD 0.0001 | PHAT US71722W1071 | Equity | 249,267 | 0 | 2.01% | $ 1.371M |
| AQUESTIVE THERAPEUTICS IN USD 0.001 | AQST US03843E1047 | Equity | 278,723 | 0 | 1.51% | $ 1.031M |
| INVENTIVA SA NPV ADR | IVA US46124U1079 | Equity | 311,468 | 0 | 1.47% | $ 1.003M |
| KYVERNA THERAPEUTICS IN USD 0.00001 | KYTX US5019761049 | Equity | 182,603 | 0 | 1.26% | $ 858.234K |
|
TELSAT 5.625 12/06/26 144A Corp
|
TELSAT 5.625 12/06/26 144A CORP US87952VAR78 | Equity | 1,000,000 | 0 | 1.22% | $ 830K |
| COMPASS PATHWAYS PLC USD 0.008 ADR | CMPS US20451W1018 | Equity | 90,381 | 0 | 1.06% | $ 721.24K |
|
ACHIEVE LIFE SCIENCES WTS
|
WTSACHV01 | Warrant | 247,593 | 0 | 0.95% | $ 646.218K |
| CELLDEX THERAPEUTICS INC USD 0.001 | CLDX US15117B2025 | Equity | 21,629 | 0 | 0.89% | $ 606.477K |
| CABALETTA BIO INC USD 0.00001 | CABA US12674W1099 | Equity | 556,235 | 0 | 0.83% | $ 567.36K |
| PROKIDNEY CORP DEL USD 0.0001 | PROK US74291D1046 | Equity | 483,741 | 0 | 0.78% | $ 532.115K |
| OPUS GENETICS INC USD 0.0001 | IRD US67577R1023 | Equity | 125,000 | 0 | 0.74% | $ 506.25K |
| OCULAR THERAPEUTIX INC USD 0.0001 | OCUL US67576A1007 | Equity | 81,051 | 0 | 0.72% | $ 487.927K |
| PALISADE BIO INC USD 0.01 | PALI US6963894026 | Equity | 434,333 | 0 | 0.64% | $ 438.676K |
|
AKERO THERAPEUTICS INC CVR
|
AKERO THERAPEUTICS INC CVR 009CVR044 | Right | 145,609 | 0 | 0.63% | $ 426.634K |
| SAB BIOTHERAPEUTICS INC USD 0.0001 | SABS US78397T2024 | Equity | 104,849 | 0 | 0.45% | $ 309.305K |
| LEONABIO INC USD 0.0001 | LONA US04746L2034 | Equity | 98,606 | 0 | 0.40% | $ 272.153K |
| CORVUS PHARMACEUTICALS I USD 0.0001 | CRVS US2210151005 | Equity | 25,000 | 0 | 0.37% | $ 254.25K |
| IMMUNIC INC USD 0.0001 | IMUX US4525EP2001 | Equity | 30,725 | 0 | 0.33% | $ 225.214K |
|
CONTRA CHINOOK THERAPE + NPV
|
US169CVR0169 | Right | 25,000 | 0 | 0.00% | $ 2,000.00 |
|
EIGER BIOPHARMACEUTICALS USD 0.0001
|
EIGRQ US28249U2042 | Equity | 90,000 | 0 | 0.00% | $ 900.00 |
|
WTS - MILESTONE PHARMACEUTICALS INC SERIES B
|
WTSMISTSB | Warrant | 1,842,974 | 0 | 0.00% | $ 1.84 |
|
WTS - TENAYA THERAPEUTICS INC
|
WTSTNYA01 | Warrant | 560,000 | 0 | 0.00% | $ 0.56 |
|
MOLECULIN BIOTECH INC WTS
|
WTSMBRX01 | Warrant | 50,000 | 0 | 0.00% | $ 0.05 |
|
WTS - QUOIN PHARMACEUTICALS LTD - Series I
|
WTSQNRX03 | Warrant | 34,895 | 0 | 0.00% | $ 0.03 |
|
WTS - QUOIN PHARMACEUTICALS LTD - Series K
|
WTSQNRX05 | Warrant | 34,895 | 0 | 0.00% | $ 0.03 |
|
ALTIMMUNE INC
|
WTSALT001 | Equity | 79,075 | 0 | 0.00% | $ 0.08 |
|
WTS - QUOIN PHARMACEUTICALS LTD - Series J
|
WTSQNRX04 | Warrant | 34,895 | 0 | 0.00% | $ 0.03 |
|
WTS - QUOIN PHARMACEUTICALS LTD - Series H
|
WTSQNRX02 | Warrant | 34,895 | 0 | 0.00% | $ 0.03 |
Trades Nov 16, 2026 to Nov 17, 2026
Changes in shares between the fund's two newest published portfolios, cash left out. Value is the change at the line's own price in the newer portfolio.
| Holding | Ticker | Action | Before | After | Change | Value |
|---|
Podcast Mentions
Sign up to see podcast mentions and sentiment
Sign Up